Figure 1.

Experimental Paradigm. Twenty male wild-type and 20 SUR-1 ^−/− mice were randomized to treatment with XMetD or control antibody. Fasting plasma glucose (FPG) and fasting insulin (FI) were measured weekly before and during the first 3 weeks of treatment. Body composition and energy expenditure were measured after 6 weeks of treatment (n = 5 per group) and a hyperinsulinemic euglycemic clamp was performed at 8 weeks (n = 5 per group).